HOME >> BIOLOGY >> NEWS
Anti-interferon beta antibodies in MS care: A consensus

SEATTLE -- February 14, 2004 -- The Consortium of Multiple Sclerosis Centers (CMSC) announced today that the presence of neutralizing antibodies (NAbs) has a significant effect on interferon beta therapy and this issue warrants the attention of health care providers and patients with multiple sclerosis (MS).

The findings, presented at the American Association for the Advancement of Science (AAAS) and National Association of Science Writers (NASW) annual meeting, state that when an MS patient develops NAbs, his/her body perceives these protein-based therapies to be "foreign," like an allergen or infection causing organism and mounts an immune response against them, basically rendering the therapy less effective.

According to Andrew R. Pachner, M.D., Professor, Department of Neurology and Neurosciences at the University of Medicine and Dentistry of New Jersey Medical School, "Patients who develop NAbs show higher relapse rates, an increased number of enlarging brain lesions, and new lesion formation compared with NAb-negative patients."

Long-Term MS Therapy and Neutralizing Antibodies

The rise of biologics (protein-based medications, which are similar to regulatory proteins normally produced by humans and generally administered by injection or infusion) has benefited countless patients in the treatment and management of chronic diseases, including cancer, anemia, diabetes, rheumatoid arthritis, psoriasis and MS.

"Biologic therapies are a significant advancement in the treatment of chronic, relapsing diseases, but in recent years, we have observed an unexpected consequence of attacking the immune system," said Frederick Munschauer, M.D., Chair, Department of Neurology, SUNY at Buffalo School of Medicine and Secretary of the Board of Governors, CMSC, and the Co-Chair of the CMSC Cooperative Studies Group in Multiple Sclerosis.

Relapsing-remitting MS patients take disease-modifying therapies called interferon betas,
'"/>

Contact: Cindy Gessell
cindy.gessell@ketchum.com
201-652-4778
Ketchum
14-Feb-2004


Page: 1 2 3

Related biology news :

1. Researchers find clues about how antibodies specialize
2. Second generation targeted antibodies - Its all in the binding
3. Researchers show autoantibodies occur before lupus in New England Journal of Medicine
4. Programmable antibodies-- hybrid cancer therapy described by scientists at Scripps
5. Bodys own antibodies may drive new strains of HIV
6. Growing human antibodies in algae
7. Blasting antibodies with lasers provides direct way of measuring their flexibilities
8. Ozone produced by antibodies during bacterial killing and in inflammation
9. Artificial antibodies created by new molecular imprinting process
10. Human antibodies against spores found by researchers suggest new tool to detect and treat anthrax
11. Scientists at The Scripps Research Institute discover a previously unknown role for antibodies

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/26/2020)... ... August 25, 2020 , ... ... for drugs, biologics, cell and gene therapies, and consumer health products, today announced ... Boston Virtual Conference & Expo, taking place between Aug. 31 – September 4, ...
(Date:8/21/2020)... ... August 18, 2020 , ... Sentien ... announced that the U.S. Food and Drug Administration (FDA) has approved the company’s ... for the treatment of severe COVID-19. Approval of this IND allows Sentien to ...
(Date:8/21/2020)... ... August 20, 2020 , ... NDA Partners Chairman ... Clinical Operations executive with expertise in clinical trial planning and feasibility, regulatory inspection ... Expert Consultant. Throughout his career, Mr. Movahhed has helped design and manage oncology, ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... ... August 11, 2020 , ... ... making available for free its new white paper – Simulated Transport Methodologies. ... into today’s biologics licensing application (BLA). In response, Modality Solutions shares an ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is now ... With 50 million stem cells total, patients may choose which extremities they would like ... arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is obtained ...
(Date:7/31/2020)... ... ... eSource has long been touted as the solution to high data management ... reasons it did not take off as quickly as people initially expected, and where ... towards capturing data electronically for clinical trials and then repurposing it for downstream analysis, ...
(Date:7/18/2020)... ... July 16, 2020 , ... “We are thrilled to deliver ... “It’s the only technology of its kind on the market and we were pleased ... the protective capacity of traditional cultured ingredients, creating a natural way to extend the ...
Breaking Biology Technology:
Cached News: